Faculty of Biology, Medicine and Health

The University of Manchester

  VariantVisualiser: Ensuring precise diagnoses of genetic disorders through the development of intuitive software that facilitates the integration and visualisation of complex informatics with biological and clinical data

  ,  Applications accepted all year round  Self-Funded PhD Students Only

About the Project

Rare diseases affect <1-in-2,000 people, but ~8,000 rare genetic diseases impact ~10% of births globally. These arise from variations in patients’ DNA sequences. To reach a diagnosis, an ecosystem of clinicians, journal publishers and databases must understand one another and agree on the specific variant(s) they are talking about. A standardised name is given to each variant so that associated diagnostic evidence can be shared. However, dataflow into clinical databases is hindered by incorrect naming of variants in the scientific literature which renders evidence undiscoverable. Additionally, there is no standardised way to record diagnostic evidence that clinicians use to classify variants as disease-causing, yielding disparities in the reliability of evidence. These seemingly minor issues contribute to ~3,000 children born annually in the UK who never receive a diagnosis. Consequently, families cannot access support they need, and up to 3,000 children die undiagnosed each year.

This proposal builds on substantial efforts of a Human Genome Organization committee which has proposed a unified professional-standard for representing genomic data which, when finalised, will be adopted world-wide. We will create visualisation software to enable the professional-standard in a framework intended to better communicate genetic data throughout the human genomics cimmunity. The framework captures precise names for variants and documents the clinical evidence used to classify them. We will upgrade the VariantValidator infrastructure to create the framework. We will then replace the existing VariantValidator interface with a new display, facilitating precise communication and interpretation of the stored clinical genomic data. Translation into tangible benefits will be facilitated by integrating of the resources into NHS training, and embedding resources into clinical pipelines, literature management systems and clinical databases. This holistic intervention will increase availability of diagnostic data enabling hundreds of thousands of children globally each year to receive a diagnosis.

Training/techniques to be provided

VariantValidator and the VariantValidator resources form part of the NHS Scientist Training Programmes in genomics and genomic bioinformatics. The student will be trained to teach trainees in the Co-Applicants digital and face-2-face training environments. Teaching is a vital part of the clinical informaticians toolkit and this training will set the student in good stead for career development and moving towards obtaining an academic position.

Entry requirements

Candidates are expected to hold (or be about to obtain) a minimum upper second-class honours degree (or equivalent) in an area/subject related to Bioinformatics or Computer Science. Programming skills in Python are essential, as is experience in SQL databases. An ideal candidate will also have experience or an interest in HTML, JavaScript, React JS.

Before you Apply

Applicants must make direct contact with preferred supervisors before applying. It is your responsibility to make arrangements to meet with potential supervisors, prior to submitting a formal online application.

How To Apply

For information on how to apply for this project, please visit the Faculty of Biology, Medicine and Health Doctoral Academy website (https://www.bmh.manchester.ac.uk/study/research/apply/). Informal enquiries may be made directly to the primary supervisor. On the online application form select PhD Bioinformatics.

For international students, we also offer a unique 4 year PhD programme that gives you the opportunity to undertake an accredited Teaching Certificate whilst carrying out an independent research project across a range of biological, medical and health sciences. For more information please visit https://www.bmh.manchester.ac.uk/study/research/programmes/integrated-teaching/

Your application form must be accompanied by a number of supporting documents by the advertised deadlines. Without all the required documents submitted at the time of application, your application will not be processed and we cannot accept responsibility for late or missed deadlines. Incomplete applications will not be considered.

If you have any queries regarding making an application please contact our admissions team .

Equality, Diversity and Inclusion

Equality, diversity and inclusion is fundamental to the success of The University of Manchester, and is at the heart of all of our activities. The full Equality, diversity and inclusion statement can be found on the website https://www.bmh.manchester.ac.uk/study/research/apply/equality-diversity-inclusion/

Biological Sciences (4) Computer Science (8)

Funding Notes

Applications are invited from self-funded students. This project has a Band 1 fee. Details of our different fee bands can be found on our website View Website

References

VariantValidator: a novel, open-access and user-friendly software to improve genetic diagnosis
R Dalgleish, P Freeman, A Brookes, L Gretton. REF 2021 Impact Development Case Study (https://results2021.ref.ac.uk/impact/468b016b-f2a7-4c7c-aa80-c2e30600a39b?page=1) 2022
Verifying nomenclature of DNA variants in submitted manuscripts: guidance for journals
J Higgins, R Dalgleish, JT den Dunnen, G Barsh, PJ Freeman, Human Mutation 42 (1), 3-7, 9, 2021
VariantValidator: Accurate validation, mapping, and formatting of sequence variation descriptions
PJ Freeman, RK Hart, LJ Gretton, AJ Brookes, R Dalgleish. Human Mutation 39 (1), 61-68, 114, 2018
Reuniting data and narrative in scientific articles. Pettifer, S., Velterop, J., Attwood, T.K., Harland, L., Marsh, J., Thorne, D. and Tunbridge, A. Insights: the UKSG journal, 25(3), p.288-293 2012. DOI: https://doi.org/10.1629/2048-7754.25.3.288
Cutting Edge: Anatomy of BioJS, an open source community for the life sciences. Guy Yachdav, Tatyana Goldberg, Steve Pettiferet al., eLife 4:e07009 2015

Open Days


Register your interest for this project



Where will I study?

Faculty of Biology, Medicine and Health

Tackle real world challenges, make a difference, and elevate your career with postgraduate research in the Faculty of Biology, Medicine and Health at Manchester. From biochemistry to neuroscience, cancer sciences to medicine, audiology to mental health and everything in between, we offer a wide range of postgraduate research projects, programmes and funding which will allow you to immerse yourself in an area of research you’re passionate about.

Why study at Faculty of Biology, Medicine and Health?

Ranked the best place to live in the UK (The Economist Global Liveability Index, 2022), Manchester boasts world-class culture, iconic sports, a thriving music and food scene, and much more. It&#39;s not just a place to research, it&#39;s a place to call home.

Experience PhD life as part of a diverse postgraduate research community of more than 1,000 postgraduate researchers at the 29th most international university in the world (Times Higher Education, 2023).

With 93% of research activity at the University rated as &#39;world-leading&#39; or &#39;internationally excellent&#39; (Research Excellence Framework, 2021), you&#39;ll get the chance to have an impact on global health and science challenges.

1000+

postgraduate students

221

PhDs

6

ranked in UK - QS (2025)

Manchester  United Kingdom

main campus

Upcoming Open Days & Webinars


About Faculty of Biology, Medicine and Health

At Manchester, postgraduate researchers are at the heart of our mission to tackle pressing global challenges in biological, medical and healthcare sciences - and you could be too.

By choosing Manchester for your postgraduate research, you’ll be joining a university with an exceptional research reputation, where 93% of research is world-leading or internationally excellent (REF, 2021) and where your work will have real-world impact.

You’ll research in world-class facilities alongside leading experts at the forefront of innovation, collaborating across disciplines to pioneer new treatments, advance scientific knowledge, and improve healthcare globally.

Supported by our dedicated Doctoral Academy and strong industry links, you'll experience PhD life in a vibrant, welcoming and diverse postgraduate research community.

And you’ll leave with the specialist knowledge, research experience and transferable skills that will shape your future in academia, research or industry.





Main campus

The University of Manchester

Manchester

North West

United Kingdom

PhD saved sucessfully

(International Partnership Studentship) Using white matter network alterations relating to stroke risk to predict cognitive and health outcomes

The project aims to investigate how age-related changes in brain white matter impact upon cognitive and health outcomes. Using advanced software and MRI data from the UK Biobank, the researchers will create effective cross-sectional and longitudinal models of how white matter abnormalities predict cognitive function. Read more
More details

(MB-PhD) Gene regulatory networks driving metastatic progression in oesophageal adenocarcinoma

Oesophageal adenocarcinoma (OAC) incidence is increasing and yet survival rates remain very poor. There are limited treatment options, especially for metastatic disease, which is especially problematic as patients usually present with late stage disease. Read more
More details

(MB-PhD) MYST Histone Acetyltransferases as Therapeutic Targets in Acute Myeloid Leukaemia

Cytotoxic chemotherapy has been the standard of care for treatment of acute myeloid leukaemia (AML) for the last 50 years. Unfortunately, more often than not, it fails to cure patients, and the 5 years survival rate for all-comers with AML is only around 20%. Read more
More details

(MB-PhD)Immunomodulation in multiple myeloma

Multiple myeloma is a devastating B-cell malignancy for which there is no cure. The development of immunomodulatory drugs (IMiDs) has proved transformative to multiple myeloma care, however, their remain unanswered questions related to the mechanism of action of this important drug class. Read more
More details

(MRC DTP CASE) Developing a cortical organoid model of genetic autism to understand early brain development

Neurodevelopmental conditions including autism and ADHD affect 4-8% of the paediatric population. These conditions present in the preschool period, are highly heritable and can severely affect quality of life, academic and occupational functioning. Read more
More details

(MRC DTP CASE) Drug Binding on human G-Protein Coupled Receptors under Tension-Altered Biomechanics in Diseases

Integral membrane proteins (MPs) constitute a significant part of the genome and are targets of ~30% of therapeutics. However, structural and functional understanding of these proteins often lags behind that of their soluble counterparts. Read more
More details

(MRC DTP) Circadian mechanisms in psoriasis: translating genomic and computational analysis to clinical care.

Despite numerous lines of evidence supporting a role for the circadian clock regulating multiple immunological axes, the dominant cell type driving rhythmic disease expression in psoriasis remains undetermined and there has been no progress on time-of-day regulation of psoriasis. Read more
More details

(MRC DTP) Combinatorial targeting of multiple disease mechanisms in drug-resistant epilepsy using microRNA inhibitors

Epilepsy is one of the most common chronic neurological diseases, affecting ~70 million people worldwide. Epilepsy is characterised by susceptibility to spontaneous seizures, and can also include challenges with cognition, sleep and mental health. Read more
More details